Assignee
ACETYLON PHARMACEUTICALS INC
US·32 granted patents·13 pending applications·185 citations·filing 2013–2023
Top patents by PatentIndex Score
45 records- 0198US9145412B2Selective HDAC1 and HDAC2 inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2013·Granted Sep 29, 2015·30 cites·32 claims
- 0297US9421212B2Selective HDAC1 and HDAC2 inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2015·Granted Aug 23, 2016·12 cites·9 claims
- 0396US9464073B2Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2015·Granted Oct 11, 2016·10 cites·12 claims
- 0496US9139583B2Selective HDAC3 inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2014·Granted Sep 22, 2015·20 cites·11 claims
- 0595US9096549B2Selective HDAC3 inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2014·Granted Aug 4, 2015·26 cites·18 claims
- 0694US9790180B2Piperidine derivatives as HDAC1/2 inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2015·Granted Oct 17, 2017·6 cites·7 claims
- 0793US9765066B2Selective HDAC1 and HDAC2 inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2016·Granted Sep 19, 2017·6 cites·14 claims
- 0890US9562013B2Selective HDAC3 inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2015·Granted Feb 7, 2017·7 cites·11 claims
- 0990US9278963B2Pyrimidine hydroxy amide compounds as histone deacetylase inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2014·Granted Mar 8, 2016·17 cites·24 claims
- 1088US9409890B2Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2013·Granted Aug 9, 2016·9 cites·8 claims
- 1187US9884850B2Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2016·Granted Feb 6, 2018·2 cites·9 claims
- 1286US9403779B2Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2014·Granted Aug 2, 2016·10 cites·4 claims
- 1385US11337975B2Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2017·Granted May 24, 2022·2 cites·5 claims
- 1485US10040769B2HDAC inhibitors for the treatment of diabetic peripheral neuropathyACETYLON PHARMACEUTICALS INC·Filed 2016·Granted Aug 7, 2018·8 cites·2 claims
- 1583US10144714B2Methods of making protein deacetylase inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2016·Granted Dec 4, 2018·3 cites·15 claims
- 1681US11324744B2Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodiesACETYLON PHARMACEUTICALS INC·Filed 2017·Granted May 10, 2022·2 cites·13 claims
- 1780US10648038B2Biomarkers to identify patients that will respond to treatment and treating such patientsACETYLON PHARMACEUTICALS INC·Filed 2017·Granted May 12, 2020·1 cites·7 claims
- 1880US9833466B2Treatment of leukemia with histone deacetylase inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2015·Granted Dec 5, 2017·5 cites·10 claims
- 1976US11357776B2Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2017·Granted Jun 14, 2022·2 cites·4 claims
- 2076US11311540B2Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugsACETYLON PHARMACEUTICALS INC·Filed 2017·Granted Apr 26, 2022·2 cites·7 claims
- 2176US10722512B2Combinations of histone deacetylase inhibitors and either HER2 inhibitors or PI3K inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2016·Granted Jul 28, 2020·1 cites·6 claims
- 2275US10370324B2Phenyl and pyridinyl hydroxamic acidsACETYLON PHARMACEUTICALS INC·Filed 2017·Granted Aug 6, 2019·1 cites·10 claims
- 2374US2023364083A1Histone deacetylase 6 (hdac6) biomarkers in multiple myelomaACETYLON PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2473US12053468B2Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2022·Granted Aug 6, 2024·0 cites·14 claims
- 2572US10927072B2Phenyl and pyridinyl hydroxamic acidsACETYLON PHARMACEUTICALS INC·Filed 2019·Granted Feb 23, 2021·0 cites·7 claims
- 2672US9949972B2Combinations of histone deacetylase inhibitors and immunomodulatory drugsACETYLON PHARMACEUTICALS INC·Filed 2014·Granted Apr 24, 2018·2 cites·7 claims
- 2771US11872227B2Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2022·Granted Jan 16, 2024·0 cites·4 claims
- 2870US11617750B2Reverse amide compounds as protein deacetylase inhibitors and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2019·Granted Apr 4, 2023·0 cites·13 claims
- 2969US2023190744A1Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3068US10464906B2Crystalline forms of a histone deacetylase inhibitorACETYLON PHARMACEUTICALS INC·Filed 2016·Granted Nov 5, 2019·1 cites·4 claims
- 3166US2020323849A1Combinations of histone deacetylase inhibitors and immunomodulatory drugsACETYLON PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3264US2020405716A1Histone deacetylase 6 (hdac6) biomarkers in multiple myelomaACETYLON PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3363US11497746B2Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2017·Granted Nov 15, 2022·0 cites·3 claims
- 3460US2016375021A1Reverse amide compounds as protein deacetylase inhibitors and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3558US2022288066A1Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugsACETYLON PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3656US2015176076A1Histone deacetylase 6 (hdac6) biomarkers in multiple myelomaACETYLON PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3750US2017096403A1Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3848US2014357512A1Histone deacetylase (hdac) biomarkers in multiple myelomaACETYLON PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3946US11998546B2Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2017·Granted Jun 4, 2024·0 cites·7 claims
- 4042US2016279128A1Pyrimidine hydroxy amide compounds as histone deacetylase inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4140US2016339022A1Treatment of neuroblastoma with histone deacetylase inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4238US11666568B2Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2017·Granted Jun 6, 2023·0 cites·6 claims
- 4336US11813261B2HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemiaACETYLON PHARMACEUTICALS INC·Filed 2017·Granted Nov 14, 2023·0 cites·8 claims
- 4436US2016228434A1Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitorACETYLON PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4526US2016137630A1Induction of gata2 by hdac1 and hdac2 inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ACETYLON PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →